Shining light on orphan receptors

October 15, 2015, Institute of Science and Technology Austria
Group photo of postdoc Álvaro Inglés-Prieto, Ph.D. student Eva Reichhart and Assistant Professor Harald Janovjak (from left to right) standing at IST Austria. Credit: IST Austria, 2015

Light has been used for the first time to activate a receptor for which the compound binding and controlling it naturally is unknown, as reported in Nature Chemical Biology today. A team of scientists including Harald Janovjak, Assistant Professor at the Institute of Science and Technology Austria (IST Austria), Álvaro Inglés-Prieto, first author and postdoc in the Janovjak group, and Eva Reichhart, PhD student in the Janovjak group, using libraries and cells from the Medical University of Vienna and the CeMM, Vienna, employed their novel application of optogenetics to identify a new compound that inhibits the orphan receptor ROS1, which has been linked to several forms of cancer.

The authors demonstrate the power of a new all-optical screening method by carrying out a screen against 'orphan' receptors. These are receptors for which the natural ligand is currently unknown. Therefore, orphan receptors can only be activated in cells using a synthetic approach, such as the artificial switch introduced in this study. Using the optical screening method, the researchers identify a new active compound that binds to and inhibits ROS1, an orphan receptor which plays a role in a variety of cancers. The inhibitory compound AV-951, also known as Tivozanib, has already been studied in clinical trials and has the potential to treat many forms of cancer.

In their novel, "all-optical", , the researchers use light as both the activator and the read-out of cellular signaling. No assay chemicals are required, which limits the number of steps required in carrying out the screen. By using LEDs, optical activation is both cheap and highly specific.

Light activation has already revolutionized neuroscience research. This study, for the first time, used light to control a protein for which the natural mode of activation is unknown. In addition, this entirely new use for expands optogenetics into the field of drug discovery.

Explore further: Enlightening cancer cells

More information: Álvaro Inglés-Prieto et al. Light-assisted small-molecule screening against protein kinases, Nature Chemical Biology (2015). DOI: 10.1038/nchembio.1933

Related Stories

Enlightening cancer cells

July 1, 2014

Joint EMBO Journal paper by IST Austria and Vienna Medical University groups on engineered cell surface receptors activated by light. Small algal protein domains serve as synthetic light sensors in human cells. First application ...

Light-activated learning

August 28, 2015

A German-French team has developed a light-sensitive switch that regulates a protein implicated in the neurobiology of synaptic plasticity. The agent promises to shed new light on the phenomenology of learning, memory and ...

Controlling movements with light

July 20, 2011

German researchers at the Ruhr-Universitaet have succeeded in controlling the activity of certain nerve cells using light, thus influencing the movements of mice. By changing special receptors in nerve cells of the cerebellum ...

Recommended for you

Coffee-based colloids for direct solar absorption

March 22, 2019

Solar energy is one of the most promising resources to help reduce fossil fuel consumption and mitigate greenhouse gas emissions to power a sustainable future. Devices presently in use to convert solar energy into thermal ...

EPA adviser is promoting harmful ideas, scientists say

March 22, 2019

The Trump administration's reliance on industry-funded environmental specialists is again coming under fire, this time by researchers who say that Louis Anthony "Tony" Cox Jr., who leads a key Environmental Protection Agency ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.